INTRODUCTION {#s1}
============

Apoptosis plays an important role in cell fate and homeostasis which is a critically in biological process \[[@R1]\]. B cell lymphoma-2 (Bcl-2) is a important protein in apoptotic pathway, and is one of the most important oncogenes in the study of apoptosis. Bcl-2 mainly located on the mitochondrial outer membrane, or by the signal stimulation after the transfer to the mitochondrial outer membrane \[[@R2]\]. Currently research shows that cancer, neurodegenerative disorders, ischemia and autoimmune diseases are associated with Bcl-2 function abnormalities \[[@R3]--[@R5]\]. High expression of Bcl-2 is associated with different cancer types, and has been reported in esophageal cancer, non-small cell lung cancer, endometrial cancer, breast cancer, prostate cancer, lung cancer, chronic lymphocytic leukemia, diffuse large B-cell lymphoma etc \[[@R6]--[@R10]\]. There is increasing evidence that Bcl-2 gene polymorphism may be associated with cancer susceptibility and prognosis.

Human Bcl-2, located on chromosome 18q21.3, consists of two promoters, which called promoter 1 (P1) and promoter 2 (P2) \[[@R11]\]. P1 and P2 have different functions. More than 95% of the BCL-2 transcription is started by P1, it is at the initial point of about 1.7 KB upstream of translation, which has no typical TATA box, but have rich in GC box that can be combined with Sp-1. Also, P1 driven transcription mainly from GC box near the beginning, this is very similar with other housekeeping gene promoter. The chromosome structure of P1 analysis showed that it could be a constitutive promoter. P2 located downstream of the P1 at about 1.3kb (at translation starting point about 80bp upstream). Compared with P1, P2 is mainly an inducible promoter, and a small part of Bcl-2 transcription is driven by the P2 \[[@R12], [@R13]\]. Previous studies have identified rs2279115 which located in P2 promoter \[[@R14]\] have conflicting results between cancer susceptibility \[[@R15]--[@R36]\] and prognosis \[[@R15], [@R18], [@R19], [@R30], [@R37]--[@R46]\]. Furthermore, the correlation between rs1801018 single nucleotide polymorphisms (SNPs) and cancer susceptibility are somewhat contradictory \[[@R29], [@R30], [@R33], [@R36], [@R47]\].

To confirm whether Bcl-2 promoter polymorphisms are related to cancer, we performed this meta-analysis, aiming to measure the correlation between Bcl-2 promoter polymorphisms and cancer susceptibility and prognosis.

RESULTS {#s2}
=======

Studies retrieved and characteristics {#s2_1}
-------------------------------------

Following an initial search, after duplicates removed, 189 studies were retrieved (PubMed: 173, Embase: 184). 6 review and 151 irrelevant studies and were excluded. Finally, 32 studies (6950 cases and 7984 controls) were chosen, and the data were extracted. A flow chart were carefully identified of the search process in Figure [1](#F1){ref-type="fig"}. The departure of Bcl-2 promoter polymorphisms frequencies from expectation under Hardy-Weinberg equilibrium (HWE) was assessed by chi-square in control group, and it was considered to be disequilibrium if P\< 0.05. Six studies were excluded by HWE expectation (P\< 0.05). The genotype distributions of all studies are summarized in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}-[3](#SD1){ref-type="supplementary-material"}.

![Flow diagram of the study selection process](oncotarget-08-25270-g001){#F1}

Overall, eighteen studies evaluating rs2279115 (6950 cases and 7984 controls) polymorphism in cancer susceptibility, three studies (1260 and 1440) evaluating rs1801018 polymorphism in cancer susceptibility, thirteen studies (4013 and 5319) evaluating rs2279115 polymorphism in cancer prognosis, and five studies (1889 and 2110) evaluating rs1801018 polymorphism in cancer prognosis. As for studies investigating the association between rs2279115 polymorphism and cancer susceptibility in cancer type, two studies evaluating rs2279115 polymorphism in cancer susceptibility in hematopoietic cancer and endocrine system cancer, three studies evaluating rs2279115 polymorphism in cancer susceptibility in digestive system cancers and respiratory cancer, four studies evaluating rs2279115 polymorphism in cancer susceptibility in breast Cancer. As for studies investigating the association between rs2279115 polymorphism and cancer susceptibility in ethnicity, eleven studies evaluating rs2279115 polymorphism in cancer susceptibility in Asia, seven studies evaluating rs2279115 polymorphism in cancer susceptibility in Caucasian. As for studies investigating the association between rs2279115 polymorphism and cancer prognostic in ethnicity, six studies evaluating rs2279115 polymorphism in cancer prognostic in Asia, seven studies evaluating rs2279115 polymorphism in cancer prognostic in Caucasian. Furthermore, three studies evaluating rs1801018 polymorphism in cancer susceptibility in Asia, and five studies evaluating rs1801018 polymorphism in cancer prognostic.

Meta-analysis of BCL-2 promoter polymorphisms and cancer susceptibility {#s2_2}
-----------------------------------------------------------------------

Overall, our results showed that rs2279115 was correlated with a significantly higher risk of cancer susceptibility in allelic, dominant, recessive, and additive models(OR= 1.16, 95% CI:1.05,1.29, P= 0.004, allelic models respectively). However, rs1801018 had no correlation with the risk of cancer susceptibility in allelic, dominant, recessive, and additive models(OR= 1.48, 95% CI:0.90,2.44, P= 0.119, allelic model respectively) in Table [1](#T1){ref-type="table"}.

###### Meta-analysis of BCL-2 promoter polymorphisms and cancer risk

                  No.ofstudies        *P*~Q~   I^2^    OR     95% CI      *P*~Z~   Model
  --------------- ------------------- -------- ------- ------ ----------- -------- ----------------------
  **rs2279115**   **18(6950/7984)**                                                
  C vs. A                             0.000    74.4%   1.16   1.05,1.29   0.004    Random-effects model
  CC+ CA vs. AA                       0.000    65.3%   1.19   1.01,1.41   0.039    Random-effects model
  CC vs. CA+AA                        0.000    67.5%   1.23   1.08,1.41   0.002    Random-effects model
  CC vs. CA                           0.004    53.8%   1.20   1.07,1.35   0.003    Random-effects model
  **rs1801018**   **3(1260/1440)**                                                 
  A vs. G                             0.034    70.4%   1.48   0.90,2.44   0.119    Random-effects model
  AA+AG vs. GG                        0.626    0.00%   1.39   0.66,2.93   0.394    Fixed-effects model
  AA vs.AG+GG                         0.039    69.1%   1.50   0.90,2.52   0.122    Random-effects model
  AA vs. AG                           0.057    65.0%   1.46   0.89,2.39   0.134    Random-effects model

Stratification was performed by cancer type, and a significant higher risk correlation between rs2279115 and cancer susceptibility was found in digestive system cancers and in allelic, dominant, recessive and additive models(OR= 1.31, 95% CI:1.18,1.45, P= 0.000, allelic model respectively), but not in breast Cancer (OR= 1.05, 95%CI:0.87,1.28, P=0.599, allelic model respectively), respiratory cancer (OR= 1.32, 95%CI:0.89,1.97, P=0.170, allelic model respectively) and Hematopoietic cancer(OR=1.19, 95%CI:0.78,1.81, P=0.418, allelic model respectively). Furthermore, we found rs2279115 was correlated with a significantly higher risk in endocrine system cancer risk in allelic (OR=1.34, 95%CI:1.06,1.71, P=0.016) and recessive model(OR=1.49, 95%CI:1.06,2.09, P=0.023), but not in dominant (OR=1.45, 95%CI:0.57,3.71, P=0.439) and additive model(OR=1.42, 95%CI:0.99,2.04, P=0.058). This is may because lack of large sample size in endocrine system cancer. Therefore, consider the inconsistency of these results, large sample size is needed in rs2279115 polymorphism and cancer susceptibility in different cancer type. Table [2](#T2){ref-type="table"} displays the results of subgroup analysis in cancer type.

###### Meta-analysis of rs2279115 polymorphism and cancer risk in cancer type

  rs2279115                      No.ofstudies       *P*~Q~   I^2^    OR     95% CI      *P*~Z~    Model
  ------------------------------ ------------------ -------- ------- ------ ----------- --------- ----------------------
  **Cancer type**                                                                                 
  **Hematopoietic cancer**       **2(333/333)**                                                   
  C vs. A                                           0.144    53.1%   1.19   0.78,1.81   0.418     Random-effects model
  CC+ CA vs. AA                                     0.586    0.00%   0.99   0.63,1.57   0.978     Fixed-effects model
  CC vs. CA+AA                                      0.130    56.4%   1.40   0.75,2.63   0.296     Random-effects model
  CC vs. CA                                         0.136    54.9%   1.48   0.74,2.82   0.272     Random-effects model
  **Digestive system cancers**   **3(1628/1640)**                                                 
  C vs. A                                           0.610    0.00%   1.31   1.18,1.45   \<0.001   Fixed-effects model
  CC+ CA vs. AA                                     0.371    0.00%   1.30   1.07,1.58   0.008     Fixed-effects model
  CC vs. CA+AA                                      0.756    0.00%   1.51   1.31,1.74   \<0.001   Fixed-effects model
  CC vs. CA                                         0.701    0.00%   1.47   1.27,1.72   \<0.001   Fixed-effects model
  **Endocrine system cancer**    **2(210/435)**                                                   
  C vs. A                                           0.203    38.3%   1.34   1.06,1.71   0.016     Fixed-effects model
  CC+ CA vs. AA                                     0.045    75.1%   1.45   0.57,3.71   0.439     Random-effects model
  CC vs. CA+AA                                      0.649    0.00%   1.49   1.06,2.09   0.023     Fixed-effects model
  CC vs. CA                                         0.856    0.00%   1.42   0.99,2.04   0.058     Fixed-effects model
  **Breast Cancer**              **4(1470/1628)**                                                 
  C vs. A                                           0.082    55.3%   1.05   0.87,1.28   0.599     Random-effects model
  CC+ CA vs. AA                                     0.005    76.5%   1.16   0.69,1.96   0.577     Random-effects model
  CC vs. CA+AA                                      0.574    0.00%   1.07   0.92,1.25   0.374     Fixed-effects model
  CC vs. CA                                         0.893    0.00%   1.03   0.87,1.21   0.742     Fixed-effects model
  **Respiratory cancer**         **3(1537/2057)**                                                 
  C vs. A                                           0.000    92.6%   1.32   0.89,1.97   0.170     Random-effects model
  CC+ CA vs. AA                                     0.001    84.7%   1.46   0.82,2.58   0.198     Random-effects model
  CC vs. CA+AA                                      0.000    91.6%   1.45   0.86,2.46   0.163     Random-effects model
  CC vs. CA                                         0.000    86.9%   1.37   0.88,2.14   0.163     Random-effects model

Stratification was performed by ethnicity, rs2279115 was correlated with a significantly higher risk of cancer susceptibility in Asia (OR= 1.28, 95% CI:1.11,1.48, P= 0.001, allelic models respectively) but not in Caucasian (OR=1.01, 95% CI:0.85,1.21, P=0.879, allelic models respectively) in allelic, dominant, recessive, and additive models. Simultaneously, rs1801018 had no correlation with the risk of cancer susceptibility in Asia in allelic, dominant, recessive, and additive models(OR= 1.48, 95% CI:0.90,2.44, P= 0.119, allelic model respectively). There is lack of data in Caucasian. Table [3](#T3){ref-type="table"} displays the results of subgroup analysis in ethnicity.

###### Meta-analysis of rs2279115 polymorphism and cancer risk in ethnicity

  rs2279115       No.ofstudies        *P*~Q~   I^2^    OR     95% CI      *P*~Z~    Model
  --------------- ------------------- -------- ------- ------ ----------- --------- ----------------------
  **Ethnicity**                                                                     
  **Asia**        **11(3869/4717)**                                                 
  C vs. A                             0.000    76.2%   1.28   1.11,1.48   0.001     Random-effects model
  CC+ CA vs. AA                       0.000    70.6%   1.39   1.07,1.82   0.014     Random-effects model
  CC vs. CA+AA                        0.000    70.9%   1.39   1.16,1.67   \<0.001   Random-effects mode
  CC vs. CA                           0.005    60.0%   1.33   1.13,1.57   0.001     Random-effects mode
  **Caucasian**   **7(3081/3267)**                                                  
  C vs. A                             0.075    56.6%   1.01   0.85,1.21   0.879     Random-effects mode
  CC+ CA vs. AA                       0.076    56.4%   1.01   0.74,1.40   0.931     Random-effects mode
  CC vs. CA+AA                        0.337    11.2%   1.03   0.89,1.19   0.710     Fixed-effects model
  CC vs. CA                           0.709    0.00%   1.02   0.87,1.19   0.814     Fixed-effects model

Meta-analysis of BCL-2 promoter polymorphism and cancer prognosis {#s2_3}
-----------------------------------------------------------------

Overall, our results showed that rs2279115 polymorphism was significantly correlated with the cancer prognosis in all four genetic models (HR=1.09, 95% CI:1.03,1.51, P= 0.000, allelic models respectively). Stratification was performed by ethnicity, rs2279115 was correlated with a significantly higher risk of cancer prognosis in Asia (HR= 1.17, 95% CI:1.01,1.41, P= 0.000, allelic models respectively) but not in Caucasian (HR=1.01, 95%CI:0.90,1.41, P=0.878, allelic models respectively). Simultaneously, there is no correlation between rs1801018 and cancer prognosis (HR=95, 95%CI:0.68,1.36, P=0.547). Table [4](#T4){ref-type="table"} displays the results of analysis.

###### Meta-analysis of BCL-2 promoter polymorphisms and cancer prognosis

  Genetic model   No.ofstudies        *P*~Q~   I^2^    HR     95% CI      *P*~Z~    Model
  --------------- ------------------- -------- ------- ------ ----------- --------- ----------------------
  **rs2279115**                                                                     
  **Total**       **13(4013/5319)**                                                 
  CC vs. CA                           0.011    59.6%   1.09   1.03,1.51   \<0.001   Random-effects model
  CC vs. AA                           0.018    58.5%   1,18   1.07,1.66   \<0.001   Random-effects model
  CA vs. AA                           0.677    0.00%   1.31   1.12,2.61   \<0.001   Fixed-effects model
  CC vs. CA+AA                        0.000    84.8%   1.26   1.16,1.71   \<0.001   Random-effects model
  **Asia**        **6(2813/3124)**                                                  
  CC vs. CA                           0.000    55.5%   1.17   1.01,1.41   \<0.001   Random-effects model
  CC vs. AA                           0.000    38.4%   1.50   1.01,2.15   \<0.001   Fixed-effects model
  CA vs. AA                           0.000    55.1%   1.38   1.03,1.87   \<0.001   Random-effects model
  CC vs. CA+AA                        0.000    53.4%   1.21   1.06,1.75   \<0.001   Random-effects model
  **Caucasian**   **7(1200/2195)**                                                  
  CC vs. CA                           0.651    0.0%    1.01   0.90,1.13   0.878     Fixed-effects model
  CC vs. AA                           0.392    5.2%    1.04   0.89,1.21   0.937     Fixed-effects model
  CA vs. AA                           0.299    15.2%   1.07   0.92,1.45   0.430     Fixed-effects model
  CC vs. CA+AA                        0.180    29.9%   1.35   0.72,2.52   0.829     Fixed-effects model
  **rs1801018**   **5(1889/2110)**                                                  
  AA vs. AG+GG                        0.088    43.6%   0.95   0.68,1.36   0.547     Fixed-effects model
  AG vs. GG                           0.610    0.0%    1.51   0.74,2.13   0.429     Fixed-effects model

Sensitivity analysis {#s2_4}
--------------------

Sensitivity analysis was conducted to assess the stability of the results. The results show rs2279115 in four genetic model were stable in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}-[4](#SD1){ref-type="supplementary-material"}, and rs1801018 in four genetic model were stable in [Supplementary Figure 5](#SD1){ref-type="supplementary-material"}-[8](#SD1){ref-type="supplementary-material"}.

Publication bias {#s2_5}
----------------

Each studies in this meta-analysis were performed to evaluate the publication bias by both Begg\'s funnel plot and Egger\'s test. P\>0.05 was considered no publication bias. The results show no obvious evidence of publication bias was found in allelic, dominant, recessive or additive genetic model in rs2279115 and rs1801018 in Table [5](#T5){ref-type="table"}.

###### Publication bias analysis of the meta-analysis

  Genetic model   Test            t       95% CI        P
  --------------- --------------- ------- ------------- -------
  **rs2279115**                                         
  C vs. A         Begg\'s test                          0.120
                  Egger\'s test   -2.73   -9.59,-1.21   0.107
  CC+ CA vs. AA   Begg\'s test                          0.272
                  Egger\'s test   -4.09   -0.84,-027    0.125
  CC vs. CA+AA    Begg\'s test                          0.472
                  Egger\'s test   3.27    1.11,5.21     0.231
  CC vs. CA       Begg\'s test                          0.791
                  Egger\'s test   1.85    -0.48,6.99    0.403
  **rs1801018**                                         
  A vs. G         Begg\'s test                          0.602
                  Egger\'s test   -4.82   -2.60,1.17    0.130
  AA+AG vs. GG    Begg\'s test                          0.117
                  Egger\'s test   -9.04   -0.09,0.02    0.070
  AA vs.AG+GG     Begg\'s test                          0.602
                  Egger\'s test   -5.03   -3.15,1.36    0.125
  AA vs. AG       Begg\'s test                          0.602
                  Egger\'s test   -5.22   -2.82,1.17    0.121

DISCUSSION {#s3}
==========

Bcl-2 is an important anti-apoptotic protein that can regulate cell death and is thus classified as an oncogene \[[@R48]\]. There is increasing evidence that Bcl-2 gene polymorphism may be associated with cancer susceptibility and prognosis. Recently,polymorphism in Bcl-2 gene, variant in promoter region rs2279115 and rs1801018, have been reported to be associated with cancer susceptibility and prognosis many times. Whether Bcl-2 promoter polymorphisms are related to cancer susceptibility and prognosis, however, the results are incompatible. This might be the first meta-analysis regarding Bcl-2 promoter polymorphisms in cancer susceptibility and prognosis.

In this study, we found that rs2279115 have a significantly higher risk of cancer susceptibility and prognosis in allelic, dominant, recessive, and additive models. However, rs1801018 had no associated with cancer susceptibility and prognosis in allelic, dominant, recessive, and additive model. Subgroups analysis indicated that rs2279115 was associated with a significantly higher risk of cancer in Asia but not in Caucasian. Furthermore, rs2279115 was associated with a significantly higher risk of cancer in digestive system cancer and endocrine system cancer but not in breast cancer, respiratory cancer and hematopoietic cancer. This is may because lack of large sample size in breast cancer, respiratory cancer and hematopoietic cancer. Therefore, consider the inconsistency of these results, large sample size is needed in rs2279115 polymorphism and cancer susceptibility in different cancer type. Simultaneously,rs2279115 was correlated with a significantly higher risk of cancer prognosis in Asia but not in Caucasian. Considering these promising results, rs2279115 may be a tumor marker for cancer therapy in Asia.

Although, we performed this meta-analysis very carefully, however, some limitations must be considered in the current meta-analysis. First, we performed stratification only by ethnicity and cancer type, without referring other factors. Further research should be conducted in other cancer type and other ethnicity population. Second, we only select literature that written by English, other language should be chosen in the further. Third, in the subgroup analysis in cancer type, there might be insufficient statistical power to check an association.

In conclusion, our meta-analysis suggests a role BCL-2 promoter polymorphisms in cancer susceptibility and prognosis, rs2279115 but not rs1801018 may be a tumor marker for cancer therapy in Asia. However, large sample size, different ethnic population and different cancer type is warranted to validate this association.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

We searched PubMed and Embase databases up to August 30, 2016, with keywords including "cancer" and "BCL-2 or B cell lymphoma-2" and "single nucleotide polymorphism or mutation or variation or SNP". We also manually checked reference lists to identify other potential studies and restricted the search to human studies. The database search was performed independently by Binhui Yang and Zhongqiu Liu and the disagreements were resolved through consensus by all of the authors.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

If the following inclusion were satisfied, studies would be included in our meta-analysis: 1) case-control studies focused on association between the Bcl-2 promoter polymorphism and cancer susceptibility or prognostic significance. 2) Studies provided sufficient data to estimate the odds ratio (OR) or hazard ratio (HR) and 95% confidence intervals (CI) according to Bcl-2 promoter polymorphisms. 3) When study patients overlapped with patients in other included studies, we selected the first study published. The two researchers (Wei Li and Qihua He) read the titles and abstracts independently and excluded the uncorrelated studies; then the full-texts were examined by our review team and the disagreements were resolved through consensus by all of the authors. The studies would be selected according to the inclusion criteria.

Data extraction {#s4_3}
---------------

The following information in studies investigating the association between Bcl-2 promoter polymorphisms and susceptibility was extracted by two independent researchers: (1) first author; (2) publication year; (3) mean value of age; (4) country and ethnicity; (5) cancer type; (6) cases and controls sample size; (7)genotype. As for studies investigating the association between Bcl-2 polymorphism and cancer prognostic, two researchers independently extracted the following information from the article:(1) first author; (2) publication year; (3) mean value of age; (4) country and ethnicity; (5) cancer type; (6) cases and controls sample size; (7) genotype; (8) HR estimation. The two researchers (Wei Li and Qihua He) read the reports independently, and the disagreements were resolved through consensus by all of the authors.

Statistical analysis {#s4_4}
--------------------

STATA software 12.0 (STATA Corp, College Station, TX, USA) were used to evaluate the relationships between Bcl-2 promoter polymorphisms and cancer susceptibility and prognosis. Studies were assessed by chi-square in control group under Hardy-Weinberg equilibrium (HWE) to calculate frequencies of BCL-2, and if P\< 0.05, study was considered to be disequilibrium. The strength of the relationship between Bcl-2 polymorphisms including rs2279115 and rs1801018 and cancer susceptibility were evaluated by odd ratios (ORs) with corresponding 95% confidence intervals (CIs). The correlation between Bcl-2 polymorphisms and cancer prognosis were measured by hazard ratios (HRs). By using Q test and I^2^ statistic to assess heterogeneity among studies in rs2279115 in the allelic (C vs. A), dominant (CC+ CA vs. AA), recessive (CC vs. CA+AA), and additive (CC vs. CA) and in rs1801018 in the allelic (A vs. G), dominant (AA+AG vs. GG), recessive (AA vs.AG+GG), and additive (AA vs. AG) genetic models. Random-effect model was chosen if P~Q~\< 0.10 or I^2^\>50%, otherwise, fixed-effect mode was applied. Sensitivity analysis was conducted to assess the stability of the results. Begg\'s and Egger\'s tests were to assess the publication bias of each study. P\< 0.05 was considered signifcant for all tests.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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